| AC Immune is a clinical stage biopharmaceutical company focused on neurodegenerative diseases with five product candidates in clinical trials. Co. utilizes its two proprietary technology platforms to discover, design and develop, proprietary small molecules, antibodies and vaccines for prevention, diagnosis and treatment of neurodegenerative diseases associated with protein misfolding. Co.'s products include: Crenezumab; ACI-24, which it owns global rights to ACI-24 and it continues to develop ACI-24 in-house as a therapeutic candidate; ACI-24 in Alzheimer's disease; ACI-24 in Down syndrome; ACI-35; Anti-Tau antibody candidate; Morphomer Tau; and diagnostic candidates. The ACIU YTD return is shown above.
The YTD Return on the ACIU YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether ACIU YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ACIU YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.